These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 17021811)
1. Change in the intrathyroidal kinetics of radioiodine under continued and discontinued antithyroid medication in Graves' disease. Dunkelmann S; Kuenstner H; Nabavi E; Rohde B; Groth P; Schuemichen C Eur J Nucl Med Mol Imaging; 2007 Feb; 34(2):228-36. PubMed ID: 17021811 [TBL] [Abstract][Full Text] [Related]
2. Lithium as an adjunct to radioiodine therapy in Graves' disease for prolonging the intrathyroidal effective half-life of radioiodine. Useful or not? Dunkelmann S; Künstner H; Nabavi E; Eberlein U; Groth P; Schümichen C Nuklearmedizin; 2006; 45(5):213-8; quiz N51-2. PubMed ID: 17043732 [TBL] [Abstract][Full Text] [Related]
3. Radioiodine therapy and thyrostatic drugs and iodine. Moka D; Dietlein M; Schicha H Eur J Nucl Med Mol Imaging; 2002 Aug; 29 Suppl 2():S486-91. PubMed ID: 12192550 [TBL] [Abstract][Full Text] [Related]
4. The effect of propylthiouracil on subsequent radioactive iodine therapy in Graves' disease. Hancock LD; Tuttle RM; LeMar H; Bauman J; Patience T Clin Endocrinol (Oxf); 1997 Oct; 47(4):425-30. PubMed ID: 9404440 [TBL] [Abstract][Full Text] [Related]
5. Outcome of pediatric Graves' disease after treatment with antithyroid medication and radioiodine. Ward L; Huot C; Lambert R; Deal C; Collu R; Van Vliet G Clin Invest Med; 1999 Aug; 22(4):132-9. PubMed ID: 10497711 [TBL] [Abstract][Full Text] [Related]
6. The effect of antithyroid drug pretreatment on acute changes in thyroid hormone levels after (131)I ablation for Graves' disease. Burch HB; Solomon BL; Cooper DS; Ferguson P; Walpert N; Howard R J Clin Endocrinol Metab; 2001 Jul; 86(7):3016-21. PubMed ID: 11443161 [TBL] [Abstract][Full Text] [Related]
7. Radioiodine therapy in Graves' disease patients with large diffuse goiters treated with or without carbimazole at the time of radioiodine therapy. Sabri O; Zimny M; Schreckenberger M; Reinartz P; Ostwald E; Buell U Thyroid; 1999 Dec; 9(12):1181-8. PubMed ID: 10646656 [TBL] [Abstract][Full Text] [Related]
8. Two-day thionamide withdrawal prior to radioiodine uptake sufficiently increases uptake and does not exacerbate hyperthyroidism compared to 7-day withdrawal in Graves' disease. Kubota S; Ohye H; Yano G; Nishihara E; Kudo T; Ito M; Fukata S; Amino N; Kuma K; Miyauchi A Endocr J; 2006 Oct; 53(5):603-7. PubMed ID: 16896267 [TBL] [Abstract][Full Text] [Related]
9. Outcomes in Relapsed Graves' Disease Patients Following Radioiodine or Prolonged Low Dose of Methimazole Treatment. Villagelin D; Romaldini JH; Santos RB; Milkos AB; Ward LS Thyroid; 2015 Dec; 25(12):1282-90. PubMed ID: 26414885 [TBL] [Abstract][Full Text] [Related]
10. Propylthiouracil reduces the effectiveness of radioiodine treatment in hyperthyroid patients with Graves' disease. Santos RB; Romaldini JH; Ward LS Thyroid; 2004 Jul; 14(7):525-30. PubMed ID: 15307942 [TBL] [Abstract][Full Text] [Related]
11. [Radioiodine therapy of Graves' disease--a dosimetric comparison of various therapy regimens of antithyroid agents]. Urbannek V; Voth E; Moka D; Schicha H Nuklearmedizin; 2001 Aug; 40(4):111-5. PubMed ID: 11556200 [TBL] [Abstract][Full Text] [Related]
12. Effect of methimazole pretreatment on serum thyroid hormone levels after radioactive treatment in Graves' hyperthyroidism. Andrade VA; Gross JL; Maia AL J Clin Endocrinol Metab; 1999 Nov; 84(11):4012-6. PubMed ID: 10566642 [TBL] [Abstract][Full Text] [Related]
13. Graves' disease and radioiodine therapy. Is success of ablation dependent on the choice of thyreostatic medication? Kobe C; Weber I; Eschner W; Sudbrock F; Schmidt M; Dietlein M; Schicha H Nuklearmedizin; 2008; 47(4):153-6. PubMed ID: 18690374 [TBL] [Abstract][Full Text] [Related]
14. Thiamazole Pretreatment Lowers the (131)I Activity Needed to Cure Hyperthyroidism in Patients With Nodular Goiter. Kyrilli A; Tang BN; Huyge V; Blocklet D; Goldman S; Corvilain B; Moreno-Reyes R J Clin Endocrinol Metab; 2015 Jun; 100(6):2261-7. PubMed ID: 25867812 [TBL] [Abstract][Full Text] [Related]
16. Radioiodine therapy of benign thyroid disorders: what are the effective thyroidal half-life and uptake of 131I? Kobe C; Eschner W; Wild M; Rahlff I; Sudbrock F; Schmidt M; Dietlein M; Schicha H Nucl Med Commun; 2010 Mar; 31(3):201-5. PubMed ID: 19907353 [TBL] [Abstract][Full Text] [Related]
17. The radioiodine turnover rate as a determinant of radioiodine treatment outcome in Graves' disease. van Isselt JW; Broekhuizen-de Gast HS Hell J Nucl Med; 2010; 13(1):2-5. PubMed ID: 20411161 [TBL] [Abstract][Full Text] [Related]
18. Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma. Luster M; Sherman SI; Skarulis MC; Reynolds JR; Lassmann M; Hänscheid H; Reiners C Eur J Nucl Med Mol Imaging; 2003 Oct; 30(10):1371-7. PubMed ID: 12856155 [TBL] [Abstract][Full Text] [Related]
19. Treatment with lithium prevents serum thyroid hormone increase after thionamide withdrawal and radioiodine therapy in patients with Graves' disease. Bogazzi F; Bartalena L; Campomori A; Brogioni S; Traino C; De Martino F; Rossi G; Lippi F; Pinchera A; Martino E J Clin Endocrinol Metab; 2002 Oct; 87(10):4490-5. PubMed ID: 12364424 [TBL] [Abstract][Full Text] [Related]
20. [F-qi-FDG PET of the thyroid gland in Graves' disease]. Börner AR; Voth E; Wienhard K; Wagner R; Schicha H Nuklearmedizin; 1998; 37(7):227-33. PubMed ID: 9830612 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]